Core Insights - Teck Resources Ltd reported quarterly earnings of $0.98 per share, exceeding the Zacks Consensus Estimate of $0.59 per share, and showing a significant increase from $0.33 per share a year ago, resulting in an earnings surprise of +67.38% [1] - The company achieved revenues of $2.19 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 8.63% and up from $1.99 billion year-over-year [2] - Teck Resources has outperformed the S&P 500, gaining approximately 24% since the beginning of the year compared to the S&P 500's gain of 0.5% [3] Earnings Outlook - The future performance of Teck Resources' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, including current consensus earnings expectations for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is $0.49 on revenues of $2 billion, while for the current fiscal year, the estimate is $2.12 on revenues of $8.27 billion [7] Industry Context - The Mining - Miscellaneous industry, to which Teck Resources belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5]

Core Insights - ImmunityBio (IBRX) shares surged 41.9% to close at $8.54, reversing a previous 7.1% loss over the past four weeks, supported by high trading volume [1][2] Company Developments - The significant share price increase was driven by the European Commission granting conditional approval for ImmunityBio's Anktiva plus BCG therapy for treating BCG-unresponsive non-muscle invasive bladder cancer, expanding its market presence to 33 countries [2] - This approval marks the first immunotherapy authorized in Europe for this specific indication, enhancing the company's growth prospects [2] Financial Expectations - ImmunityBio is projected to report a quarterly loss of $0.08 per share, reflecting a year-over-year increase of 46.7%, with expected revenues of $37.1 million, up 391.4% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 6.3% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - ImmunityBio operates within the Zacks Medical - Biomedical and Genetics industry, where Mirum Pharmaceuticals, another company in the sector, has seen a 2.2% increase in its stock price, closing at $105.1, with an 11.9% return over the past month [4] - Mirum Pharmaceuticals has a consensus EPS estimate that has changed by +50.9% over the past month, indicating a significant year-over-year change of +104.1% [5]

Core Insights - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List, indicating a negative outlook for these companies [1][2]. Company Summaries - **Cenovus Energy Inc. (CVE)**: This company is involved in the exploration and production of crude oil, natural gas, and natural gas liquids. The Zacks Consensus Estimate for its current year earnings has been revised nearly 2% downward over the last 60 days [1]. - **Ispire Technology Inc. (ISPR)**: This company designs and sells vaping devices and cannabis products globally. The Zacks Consensus Estimate for its current year earnings has been revised 162.5% downward over the last 60 days [1]. - **Kyndryl Holdings, Inc. (KD)**: A technology services company, Kyndryl has seen its Zacks Consensus Estimate for current year earnings revised 9.4% downward over the last 60 days [2].

Core Insights - The article highlights the performance and outlook of several companies, including Applied Materials, McDonald's, Texas Instruments, and Lulu's Fashion Lounge Holdings, based on recent research reports from Zacks Equity Research. Group 1: Applied Materials, Inc. (AMAT) - Shares have outperformed the Zacks Electronics - Semiconductors industry over the past six months, increasing by 126.3% compared to the industry's 22.1% [4] - The company benefits from a rebound in the semiconductor industry, particularly in the foundry and logic sectors, along with consistent progress in its services and strength in various business segments [5] - Concerns include increasing U.S.-China tensions, export restrictions on semiconductor manufacturing equipment, slow memory market recovery, and rising operating costs [6] Group 2: McDonald's Corp. (MCD) - Shares have outperformed the Zacks Retail - Restaurants industry over the past six months, with a growth of 7.2% compared to 2.9% for the industry [7] - The company reported fourth-quarter 2025 results that exceeded Zacks Consensus Estimates, with year-over-year increases in both earnings and revenues [8] - McDonald's is focusing on aggressive unit expansion, targeting 50,000 restaurants worldwide by 2027, despite facing financial pressures and declining earnings estimates for fiscal 2026 [9] Group 3: Texas Instruments Inc. (TXN) - Shares have outperformed the Zacks Semiconductor - General industry over the past six months, increasing by 17.7% compared to 2.9% for the industry [10] - The company is experiencing solid demand in data centers, which enhances its prospects in the enterprise systems market, supported by a focus on expanding its product portfolio [11] - Growth may be hindered by a slow recovery in the industrial market, rising manufacturing costs, and ongoing U.S.-China tech tensions [12] Group 4: Lulu's Fashion Lounge Holdings, Inc. (LVLU) - Shares have significantly outperformed the Zacks Retail - Apparel and Shoes industry, with a remarkable increase of 250.1% compared to 18.6% for the industry [13] - The company is expanding its multi-channel growth strategy, including a full entry into all Nordstrom stores by February 2026, following a 143% year-over-year growth in wholesale revenue [14] - Despite the growth, liquidity is constrained, with only $6.8 million in credit headroom and $1.9 million in cash, alongside persistent net losses and declining active customers [15]

Company Overview - Asure Software Inc (ASUR) shares increased by 5.9% to $7.57 in the last trading session, following a significant volume of shares traded, contrasting with a 22.1% loss over the past four weeks [1] - The company is experiencing broad-based revenue growth in its Human Capital Management portfolio, with improvements in organic growth and contributions from the Lathen Time Acquisition [1] Earnings Expectations - Asure Software is projected to report quarterly earnings of $0.23 per share, reflecting a year-over-year increase of 53.3% [2] - Expected revenues for the upcoming quarter are $38.67 million, which is a 25.6% increase compared to the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Asure Software has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Context - Asure Software is part of the Zacks Internet - Delivery Services industry, where another company, GoDaddy (GDDY), saw a 0.7% decrease in its stock price, with a return of -11.9% over the past month [3] - GoDaddy's consensus EPS estimate for its upcoming report is $1.58, representing an 11.3% increase from the previous year, and it holds a Zacks Rank of 2 (Buy) [4]

Core Insights - Carvana reported record Q4 and full-year results, with stock increasing by 3% following the announcement [1] - The company sold 163,522 vehicles in Q4 and nearly 600,000 vehicles in 2025, marking a 43% year-over-year growth [1][2] Q4 Results - Q4 sales reached $5.6 billion, a 58% increase from $3.54 billion in the same quarter last year, exceeding estimates by 7% [3] - Q4 EPS was $4.22, surpassing expectations of $1.13 by 273% and up from $0.56 per share a year ago [4] - Cash from operating activities increased by 617% year-over-year to $430 million, indicating strong cash generation [5] Full Year Results & Strategic Goals - Total sales for fiscal 2025 rose 49% to $20.3 billion from $13.67 billion in 2024, with net income increasing to $1.9 billion [9] - Full-year EPS surged 405% to a record $8.04, compared to $1.59 per share in 2024 [9] - Carvana aims for significant growth in retail units sold and adjusted EBITDA in 2026, with projected sequential increases in Q1 [10] Valuation Monitoring - Carvana stock is trading at a forward earnings multiple of 43X, closer to the S&P 500 benchmark and the Zacks Internet-Commerce Industry average [11] - The price to forward-sales ratio is under 3X, which is a discount compared to the S&P 500's 5X [11] Bottom Line - Carvana currently holds a Zacks Rank 3 (Hold), with potential for a buy rating as EPS revisions are expected to trend higher for FY26 [13] - The stock's pullback from its all-time high of $486 per share is seen as more attractive as bubble fears diminish [13]

Core Insights - ONE Gas reported revenue of $689.37 million for the quarter ended December 2025, reflecting a 9.3% increase year-over-year and a 2.1% surprise over the Zacks Consensus Estimate of $675.21 million [1] - The earnings per share (EPS) for the quarter was $1.48, up from $1.34 in the same quarter last year, with a surprise of 4.04% over the consensus estimate of $1.42 [1] Financial Performance Metrics - Natural gas sales volumes for transportation were reported at 56,800.00 MMcf, below the average estimate of 58,722.75 MMcf [4] - Total sales volumes delivered were 46,900.00 MMcf, exceeding the average estimate of 45,791.98 MMcf [4] - Total volumes delivered were 103,700.00 MMcf, slightly below the average estimate of 104,514.70 MMcf [4] - Residential natural gas sales volumes were 34,900.00 MMcf, compared to the average estimate of 35,944.91 MMcf [4] - Commercial and industrial sales volumes were reported at 11,200.00 MMcf, close to the average estimate of 11,281.46 MMcf [4] - Total customers were reported at 2,290, slightly below the average estimate of 2,292 [4] Revenue Breakdown - Transportation revenues were $39.1 million, lower than the average estimate of $47.38 million, but showed a year-over-year increase of 4.6% [4] - Natural gas sales revenues reached $629.1 million, surpassing the average estimate of $580.05 million, marking a year-over-year increase of 9.7% [4] Stock Performance - ONE Gas shares have returned +9.1% over the past month, contrasting with the Zacks S&P 500 composite's -1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Nutrien reported a revenue of $5.34 billion for the quarter ended December 2025, marking a year-over-year increase of 5.1% and exceeding the Zacks Consensus Estimate by 2.55% [1] Financial Performance - Earnings per share (EPS) for the quarter was $0.83, compared to $0.31 a year ago, although it fell short of the consensus estimate of $0.87 by 4.96% [1] - Nutrien's stock has returned +3.9% over the past month, outperforming the Zacks S&P 500 composite, which declined by -1.3% [3] Sales Metrics - Potash sales volumes totaled 2,803 KTon, below the average estimate of 2,876.83 KTon [4] - Nitrogen sales volumes reached 2,575 KTon, also below the average estimate of 2,667.94 KTon [4] - Average selling price per tonne for phosphate (industrial and feed) was $875, exceeding the average estimate of $713.89 [4] - Retail sales (Nutrient Ag Solutions) amounted to $3.14 billion, slightly below the estimated $3.21 billion, reflecting a -1.1% change year-over-year [4] - Potash sales were reported at $792 million, a +34.9% increase year-over-year, but below the estimate of $804.4 million [4] - Nitrogen sales reached $1.24 billion, surpassing the estimate of $1.09 billion, with a year-over-year increase of +5.4% [4] - Phosphate sales were $543 million, exceeding the average estimate of $513.52 million, representing a +15.3% year-over-year change [4] - Net sales for phosphate were $483 million, above the estimate of $421.42 million, with a +16.7% year-over-year change [4] - Net sales for potash were $736 million, exceeding the estimate of $706.92 million, reflecting a +37.3% year-over-year change [4] - Net sales for nitrogen were $1.09 billion, surpassing the estimate of $990.83 million, with a +7.9% year-over-year change [4]

Core Insights - Bausch Health reported revenue of $2.8 billion for the quarter ended December 2025, reflecting a year-over-year increase of 9.3% and exceeding the Zacks Consensus Estimate of $2.7 billion by 3.38% [1] - The company's EPS was $1.08, down from $1.15 in the same quarter last year, resulting in an EPS surprise of -10.5% compared to the consensus estimate of $1.21 [1] Revenue Breakdown - Total Bausch + Lomb revenues reached $1.41 billion, surpassing the average estimate of $1.37 billion by analysts, marking a year-over-year increase of 9.8% [4] - Revenues from Diversified Products were $255 million, exceeding the estimated $233.84 million, with an 11.8% increase year-over-year [4] - Bausch + Lomb's Vision Care segment generated $778 million, closely matching the average estimate of $778.13 million, reflecting a 7.6% year-over-year growth [4] - Surgical revenues amounted to $249 million, above the average estimate of $239.46 million, indicating a 7.8% increase year-over-year [4] - Total revenues excluding Bausch + Lomb were $1.39 billion, exceeding the $1.33 billion estimate, with an 8.8% year-over-year growth [4] - International revenues were reported at $306 million, surpassing the average estimate of $280.41 million, representing a 9.7% year-over-year increase [4] - Solta Medical revenues were $137 million, slightly below the average estimate of $143.46 million, showing a year-over-year decline of 0.7% [4] - Salix revenues reached $693 million, exceeding the estimated $669.92 million, with a year-over-year increase of 9.3% [4] - Bausch + Lomb Pharmaceuticals generated $378 million, surpassing the average estimate of $353.78 million, reflecting a significant year-over-year growth of 16% [4] Stock Performance - Bausch shares have returned -11.8% over the past month, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Blue Owl Capital Corporation reported $447.75 million in revenue for Q4 2025, a 13.5% year-over-year increase, with an EPS of $0.36 compared to $0.47 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $446.15 million by 0.36%, while the EPS surpassed the consensus estimate of $0.35 by 1.9% [1] Financial Performance Metrics - Investment income from non-controlled, non-affiliated investments showed a significant year-over-year increase of 18.6% in interest income, totaling $340.58 million, surpassing the average estimate of $334.04 million [4] - Other income from non-controlled, non-affiliated investments decreased by 16.3% year-over-year to $4.87 million, below the average estimate of $5.54 million [4] - Dividend income from controlled, affiliated investments increased by 55.8% year-over-year to $39.54 million, exceeding the average estimate of $38.3 million [4] - Total investment income from non-controlled, non-affiliated investments rose by 10.5% year-over-year to $396.25 million, surpassing the average estimate of $390.37 million [4] - Total investment income from controlled, affiliated investments increased by 50.3% year-over-year to $50.58 million, exceeding the average estimate of $48.63 million [4] Stock Performance - Over the past month, shares of Blue Owl Capital Corporation have returned -8%, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]